Colgate-Palmolive Company
CL
$93.00
-0.30%
Colgate-Palmolive Company is a global leader in consumer products, manufacturing and selling oral care, personal care, home care, and pet nutrition products across more than 200 countries. With a heritage dating back to 1806, the company holds dominant market positions in oral care (over 40% of sales) and operates a highly profitable specialty pet food business through Hill's, which contributes nearly a quarter of revenue. The current investor narrative centers on the company's ability to sustain organic growth amid a rotation toward defensive consumer staples, while managing input cost inflation and currency headwinds. Recent attention has also focused on the company's premium valuation relative to peers, as investors debate whether its defensive characteristics justify the multiple in a rising rate environment.…
CL
Colgate-Palmolive Company
$93.00
Investment Opinion: Should I buy CL Today?
Based on the analysis, CL is rated a Buy. The thesis is that Colgate-Palmolive's defensive characteristics, accelerating revenue growth, and strong cash generation justify its premium valuation, with analyst targets implying upside. The consensus rating is 'Buy' with an average target of $97.65, representing a 6.95% upside from the current price of $91.30.
Sign up to view all
CL 12-Month Price Forecast
The AI model assesses CL as bullish with medium confidence, driven by strong revenue acceleration and margin stability. The premium valuation is justified by defensive quality and consistent cash flows. However, high debt and payout ratio temper confidence. Upgrades would occur if revenue growth exceeds 10% and margins expand; downgrades if growth falls below 5% or margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $98.95 and implied upside of +6.4% versus the current price.
Average Target
$98.95
0 analysts
Implied Upside
+6.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $110
Analyst target range
The target price range spans from $85.00 to $110.00, with the low target implying a downside of 6.9% and the high target implying an upside of 20.5%. The wide spread of $25 indicates significant uncertainty about the stock's future performance, likely reflecting varying views on the sustainability of growth and the impact of input costs. The high target of $110 assumes continued market share gains and successful premiumization, while the low target of $85 factors in potential margin compression from raw material inflation and competitive pressures. Recent institutional actions have been predominantly positive, with Rothschild & Co upgrading from Neutral to Buy in April 2026, and no downgrades in the past three months, reinforcing the constructive sentiment.
Bulls vs Bears: CL Investment Factors
Colgate-Palmolive presents a balanced risk/reward profile, with strong revenue growth, high gross margins, and defensive characteristics offset by a premium valuation and high debt. The bull case is supported by accelerating organic growth and analyst optimism, while the bear case hinges on valuation and leverage concerns. Currently, the bull case has slightly stronger evidence given the company's proven pricing power and consistent cash generation. The most critical tension is whether the premium valuation can be justified by sustained earnings growth; if growth decelerates, the stock could face multiple compression.
Bullish
- Strong Revenue Acceleration: Q1 2026 revenue grew 8.41% YoY to $5.324B, up from 4.91% in the prior year quarter, indicating accelerating organic growth driven by pricing and volume. This momentum is broad-based across Oral, Personal, Home Care, and Pet Nutrition segments.
- High Gross Margin Expansion: Gross margin improved to 60.59% in Q1 2026 from 60.82% in Q1 2025, reflecting successful pricing actions and cost discipline. This supports the company's ability to protect profitability despite input cost inflation.
- Defensive Characteristics with Low Beta: With a beta of 0.319, CL offers significant downside protection in volatile markets, making it an attractive defensive holding. Its consistent demand for household essentials provides stable cash flows.
- Analyst Consensus Buy with Upside: The average analyst target of $97.65 implies a 6.95% upside from the current price of $91.30, with a high target of $110 suggesting 20.5% potential. The consensus rating is 'Buy' with a mean score of 2.10, reflecting positive sentiment.
Bearish
- Premium Valuation with High PE: The trailing PE of 29.93x and forward PE of 22.50x are at a premium to the broader market, pricing in significant earnings growth. The PEG ratio is negative (-1.19), indicating that growth expectations may be too optimistic relative to historical earnings growth.
- High Debt Levels: Debt-to-equity ratio of 147.93x is elevated, reflecting significant leverage. This increases financial risk, especially if interest rates remain high or cash flows weaken.
- Underperformance vs. Market: CL's 1-year return of +8.88% lags the S&P 500's +18.19%, and relative strength over 1 year is -9.31%. This suggests the stock is not participating fully in market rallies, possibly due to valuation concerns.
- High Payout Ratio Limits Growth: The payout ratio of 85.5% leaves little room for dividend increases or reinvestment, potentially constraining future growth. This could make the stock less attractive to growth-oriented investors.
CL Technical Analysis
Colgate-Palmolive's stock has been in a clear uptrend over the past year, with a 1-year price change of +8.88%, though this lags the S&P 500's +18.19% gain. The current price of $91.30 sits at 82.5% of the 52-week range (between $74.55 low and $99.33 high), indicating the stock is closer to its highs but not at overbought extremes. This positioning suggests a constructive trend, but the relative underperformance versus the broader market highlights a defensive posture that may be losing some momentum.
Beta
0.33
0.33x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+9.9%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | -2.1% | +2.8% |
| 3m | +6.2% | +4.2% |
| 6m | -1.5% | +11.3% |
| 1y | +9.9% | +21.5% |
| ytd | +19.7% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Colgate-Palmolive's revenue growth has been steady, with the most recent quarter (Q1 2026) reporting revenue of $5.324 billion, up 8.41% year-over-year. This marks an acceleration from the prior year's growth rates, as Q1 2025 revenue was $4.911 billion, and sequential quarters have shown consistent expansion from $5.11 billion in Q2 2025 to $5.23 billion in Q4 2025. The growth is broad-based, with Oral, Personal and Home Care contributing $4.034 billion and Pet Nutrition adding $1.196 billion in the latest quarter. The company's ability to drive volume and pricing in a challenging consumer environment underscores its brand strength and pricing power.
Quarterly Revenue
$5.3B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
60.6%
Latest Quarter
Free Cash Flow
$3.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Given Colgate-Palmolive's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 29.93x, while the forward PE is 22.50x, implying the market expects earnings growth of approximately 33% over the next year. This gap suggests investors are pricing in a significant acceleration in profitability, likely driven by margin expansion and continued revenue growth. The forward PE of 22.5x is at a premium to the broader market, reflecting the company's defensive quality and consistent cash generation.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Colgate-Palmolive carries a high debt-to-equity ratio of 147.93x, which amplifies vulnerability to rising interest rates and economic downturns. The payout ratio of 85.5% leaves minimal retained earnings for reinvestment, potentially limiting future growth. While free cash flow is strong at $3.767B, the company's reliance on continued revenue growth to justify its premium valuation is a key risk; any slowdown could trigger de-rating. Additionally, the negative PEG ratio (-1.19) suggests that earnings growth expectations may be too optimistic relative to historical trends, increasing the risk of disappointment.
FAQ
Key risks include: 1) High debt levels (D/E 147.93x) increasing financial vulnerability; 2) Premium valuation leaving little room for error; 3) Input cost inflation and currency headwinds pressuring margins; 4) High payout ratio (85.5%) limiting reinvestment. The most severe risk is a growth slowdown that triggers multiple compression, potentially leading to a 20%+ decline.
The 12-month forecast is moderately bullish. The base case (50% probability) targets $92-$100, aligning with the analyst average of $97.65. The bull case (30%) targets $100-$110, while the bear case (20%) targets $80-$85. The most likely scenario is the base case, assuming continued revenue growth of 6-8% and stable margins.
CL is trading at a premium to the broader market, with a trailing PE of 29.93x and forward PE of 22.50x. This premium reflects its defensive quality and consistent growth, but it also implies high expectations. Compared to its own history, the current valuation is above the 5-year average, suggesting it is not undervalued. The market is pricing in significant earnings growth, which may be optimistic given the negative PEG ratio.
CL is a good buy for investors seeking defensive exposure with moderate growth. The analyst consensus is 'Buy' with an average target of $97.65, implying a 6.95% upside. The stock offers a 2.85% dividend yield and strong free cash flow, but the premium valuation (forward PE 22.5x) and high debt (D/E 147.93x) warrant caution. It is best suited for long-term investors who can tolerate valuation fluctuations in exchange for stability.
CL is best suited for long-term investment due to its defensive nature, low beta (0.319), and consistent dividend payments. Short-term trading may be limited by its low volatility and modest upside. A minimum holding period of 3-5 years is recommended to fully benefit from its compounding earnings and dividend growth.